ials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.
Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.
About Hereditary Angioedema (HAE)
HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,000 people with HAE in the United States.
For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceu
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE ViroPharma Incorporated|
Copyright©2009 PR Newswire.
All rights reserved
. ViroPharma to Present at Two June Healthcare Conferences2
. ViroPharma Incorporated Honored by the National Organization for Rare Disorders3
. ViroPharma Incorporated Reports First Quarter 2009 Financial Results4
. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 20095
. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes6
. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results7
. ViroPharma to Present at Three November Healthcare Conferences8
. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business9
. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 200810
. ViroPharma to Present at Three October Healthcare Conferences11
. ViroPharma to Present at Three September Healthcare Conferences